

CRITERIA FOR PRIOR AUTHORIZATION

Afinitor® (everolimus)

PROVIDER GROUP	Pharmacy
MANUAL GUIDELINES	The following drug requires prior authorization: Everolimus (Afinitor Disperz & Tablets)

CRITERIA FOR ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER (TABLETS ONLY): (must meet all of the following)

- Patient must be postmenopausal
- Patient must have a diagnosis of advanced hormone receptor-positive, HER2-negative breast cancer (HR+ BC)
- Must be used in combination with exemestane, after failure of treatment with letrozole or anastrozole
- Patient must not be taking Afinitor Disperz concurrently

CRITERIA FOR ADVANCED NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (TABLETS ONLY): (must meet all of the following)

- Patient must have a diagnosis of progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease
- Patient must not be taking Afinitor Disperz concurrently
- Patient must not be pregnant

CRITERIA FOR ADVANCED RENAL CELL CARCINOMA (TABLETS ONLY): (must meet all of the following)

- Patient must have a diagnosis of advanced renal cell carcinoma (RCC)
- Patient must have failed treatment with sunitinib or sorafenib
- Patient must not be taking Afinitor Disperz concurrently
- Patient must not be pregnant

CRITERIA FOR RENAL ANGIOMYOLIPOMA WITH TUBEROUS SCLEROSIS COMPLEX (TABLETS ONLY): (must meet all of the following)

- Patient must have renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery
- Patient must not be taking Afinitor Disperz concurrently
- Patient must not be pregnant

CRITERIA FOR SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) WITH TUBEROUS SCLEROSIS COMPLEX (TSC) (TABLETS & DISPERZ): (must meet all of the following)

- Patient must have tuberous sclerosis complex (TSC) with subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected
- Patient must not be taking Afinitor tablets and Disperz concurrently
- Patient must not be pregnant

CRITERIA FOR WALDENSTROM'S MACROGLOBULINEMIA (TABLETS ONLY): (must meet all of the following)

- Patient must have a diagnosis of Waldenstrom's Macroglobulinemia (lymphoplasmcytic lymphoma)
- Patient must not be taking Afinitor Disperz concurrently
- Patient must not be pregnant

PA Criteria

CRITERIA FOR LUNG NEUROENDOCRINE TUMORS (TABLETS ONLY): (must meet all of the following)

- Patient must have a diagnosis of lung neuroendocrine tumors
- Patient must not be taking Afinitor Disperz concurrently
- Patient must not be pregnant

CRITERIA FOR NEUROENDOCRINE TUMORS (TABLETS ONLY): (must meet all of the following)

- Patient must have a diagnosis of progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic
- Patient must not be taking Afinitor Disperz concurrently
- Patient must not be pregnant

LENGTH OF APPROVAL 12 months